Study details
Enrolling now
Cytotoxic T Lymphocytes for Treating Malignancies With BK and/or JC Virus
M.D. Anderson Cancer Center
NCT IDNCT02479698ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
100
Study length
about 12 years
Ages
All ages
Locations
1 site in TX
About this study
This trial is testing if donor cytotoxic T lymphocytes can help treat patients with malignancies that have BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells grown in a lab to kill viruses, potentially offering an effective treatment option for these specific cancers.
Based on ClinicalTrials.gov records.
What participants do
- 1.Laboratory Biomarker Analysis
- 2.Receive Allogeneic BK-specific Cytotoxic T-lymphocytes
PhasePhase 2
Primary goalIncidence of adverse events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Incidence of adverse events
Secondary: Overall survival
Body systems
Oncology, Immune, Infectious